ClinicalTrials.gg

Program

ML-007C

A development code. Also written as “ML-007C-MA”, “ML-007C-MA BID” and “ML-007C-MA QD”.

Its studies are mostly in Alzheimer Disease · Schizophrenia, led by MapLight Therapeutics.

Furthest: phase 2, since Mar 14, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MapLight Therapeutics43 open or runningphase 2since Mar 14, 2025Mar 14, 2025Dec 2027phase 2 · NCT06887192

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 14, 2025First study: phase 2 study in Alzheimer DiseaseFirst studyNCT06887192 · 300 planned · United States, Argentina, Bulgaria and more
  2. Jun 18, 2025Phase 2 study in SchizophreniaNCT07038876 · 307 enrolled · United States
  3. Mar 5, 20262 phase 2 studiesNCT07459660, NCT07459647

Ahead

  1. Dec 2027Primary completion: phase 2 study in Alzheimer DiseaseNCT06887192
  2. Mar 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07459660
  3. Feb 2030Primary completion: phase 2 study in SchizophreniaNCT07459647

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07459660Alzheimer Disease · United States, Bulgaria, France2By invitationMar 2029210
NCT07459647Schizophrenia · United States2RecruitingFeb 2030500
NCT07038876Schizophrenia · United States2CompletedJun 4, 2026307
NCT06887192Alzheimer Disease · United States, Argentina, Bulgaria and more2RecruitingDec 2027300

How it is read

Names in the registry

  • “ML-007C-MA”, 3 entries
  • “ML-007C-MA BID”, 1 entry
  • “ML-007C-MA QD”, 1 entry

Codes read as this program: ML007C.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.